Tuan Tony Tran, PharmD, MBA

TV-44749 is a subcutaneous long-acting injectable form of olanzapine that is effective in schizophrenia while avoiding risks seen with the intramuscular formulation.

Pharmacists optimize dopaminergic therapy, mitigate medication-induced psychosis, and guide antipsychotic selection to improve outcomes in Parkinson disease psychosis.

Pimavanserin offers a serotonin-targeted option for Parkinson disease psychosis that improves hallucinations and delusions with minimal impact on motor symptoms.